Literature DB >> 12956774

Structure-function analysis of the extracellular domains of the Duffy antigen/receptor for chemokines: characterization of antibody and chemokine binding sites.

Christophe Tournamille1, Anne Filipe, Kazimiera Wasniowska, Pierre Gane, Elwira Lisowska, Jean-Pierre Cartron, Yves Colin, Caroline Le Van Kim.   

Abstract

The Duffy antigen/receptor for chemokines (DARC), a seven-transmembrane glycoprotein carrying the Duffy (Fy) blood group, acts as a widely expressed promiscuous chemokine receptor. In a structure-function study, we analysed the binding of chemokines and anti-Fy monoclonal antibodies (mAbs) to K562 cells expressing 39 mutant forms of DARC with alanine substitutions spread out on the four extracellular domains (ECDs). Using synthetic peptides, we defined previously the Fy6 epitope (22-FEDVW-26), and we characterized the Fya epitope as the linear sequence 41-YGANLE-46. In agreement with these results, mutations of F22-E23, V25 and Y41, G42, N44, L45 on ECD1 abolished the binding of anti-Fy6 and anti-Fya mAbs to K562 cells respectively, Anti-Fy3 binding was abolished by D58-D59 (ECD1), R124 (ECD2), D263 and D283 (ECD4) substitutions. Mutations of C51 (ECD1), C129 (ECD2), C195 (ECD3) and C276 (ECD4 severely reduced anti-Fy3 and CXC-chemokine ligand 8 (CXCL-8) binding. CXCL-8 binding was also abrogated by mutations of F22-E23, P50 (ECD1) and D263, R267, D283 (ECD4). These results defined the Fya epitope and suggested that (1) two disulphide bridges are involved in the creation of an active chemokine binding pocket; (2) a limited number of amino acids in ECDs 1-4 participate in CXCL-8 binding; and (3) Fy3 is a conformation-dependent epitope involving all ECDs. We also showed that N-glycosylation of DARC occurred on N16SS and did not influence antibody and chemokine binding.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12956774     DOI: 10.1046/j.1365-2141.2003.04533.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  16 in total

1.  A recombinant dromedary antibody fragment (VHH or nanobody) directed against human Duffy antigen receptor for chemokines.

Authors:  Dorota Smolarek; Claude Hattab; Gholamreza Hassanzadeh-Ghassabeh; Sylvie Cochet; Carlos Gutiérrez; Alexandre G de Brevern; Rachanee Udomsangpetch; Julien Picot; Magdalena Grodecka; Kazimiera Wasniowska; Serge Muyldermans; Yves Colin; Caroline Le Van Kim; Marcin Czerwinski; Olivier Bertrand
Journal:  Cell Mol Life Sci       Date:  2010-05-11       Impact factor: 9.261

Review 2.  In silico studies on DARC.

Authors:  Alexandre G de Brevern; Ludovic Autin; Yves Colin; Olivier Bertrand; Catherine Etchebest
Journal:  Infect Disord Drug Targets       Date:  2009-06

Review 3.  Chemokine receptor internalization and intracellular trafficking.

Authors:  Nicole F Neel; Evemie Schutyser; Jiqing Sai; Guo-Huang Fan; Ann Richmond
Journal:  Cytokine Growth Factor Rev       Date:  2005-07-05       Impact factor: 7.638

4.  Strict tropism for CD71+/CD234+ human reticulocytes limits the zoonotic potential of Plasmodium cynomolgi.

Authors:  Varakorn Kosaisavee; Rossarin Suwanarusk; Adeline C Y Chua; Dennis E Kyle; Benoit Malleret; Rou Zhang; Mallika Imwong; Rawiwan Imerbsin; Ratawan Ubalee; Hugo Sámano-Sánchez; Bryan K S Yeung; Jessica J Y Ong; Eric Lombardini; François Nosten; Kevin S W Tan; Pablo Bifani; Georges Snounou; Laurent Rénia; Bruce Russell
Journal:  Blood       Date:  2017-07-11       Impact factor: 22.113

5.  Species-specific features of DARC, the primate receptor for Plasmodium vivax and Plasmodium knowlesi.

Authors:  Ann Demogines; Kimberly A Truong; Sara L Sawyer
Journal:  Mol Biol Evol       Date:  2011-08-30       Impact factor: 16.240

6.  Staphylococcus aureus Targets the Duffy Antigen Receptor for Chemokines (DARC) to Lyse Erythrocytes.

Authors:  András N Spaan; Tamara Reyes-Robles; Cédric Badiou; Sylvie Cochet; Kristina M Boguslawski; Pauline Yoong; Christopher J Day; Carla J C de Haas; Kok P M van Kessel; François Vandenesch; Michael P Jennings; Caroline Le Van Kim; Yves Colin; Jos A G van Strijp; Thomas Henry; Victor J Torres
Journal:  Cell Host Microbe       Date:  2015-08-27       Impact factor: 21.023

7.  Opposing roles of murine duffy antigen receptor for chemokine and murine CXC chemokine receptor-2 receptors in murine melanoma tumor growth.

Authors:  Linda W Horton; Yingchun Yu; Snjezana Zaja-Milatovic; Robert M Strieter; Ann Richmond
Journal:  Cancer Res       Date:  2007-10-15       Impact factor: 12.701

8.  Sequence, evolution and ligand binding properties of mammalian Duffy antigen/receptor for chemokines.

Authors:  Christophe Tournamille; Antoine Blancher; Caroline Le Van Kim; Pierre Gane; Pol André Apoil; Wilson Nakamoto; Jean Pierre Cartron; Yves Colin
Journal:  Immunogenetics       Date:  2004-01-08       Impact factor: 2.846

Review 9.  International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors.

Authors:  Francoise Bachelerie; Adit Ben-Baruch; Amanda M Burkhardt; Christophe Combadiere; Joshua M Farber; Gerard J Graham; Richard Horuk; Alexander Hovard Sparre-Ulrich; Massimo Locati; Andrew D Luster; Alberto Mantovani; Kouji Matsushima; Philip M Murphy; Robert Nibbs; Hisayuki Nomiyama; Christine A Power; Amanda E I Proudfoot; Mette M Rosenkilde; Antal Rot; Silvano Sozzani; Marcus Thelen; Osamu Yoshie; Albert Zlotnik
Journal:  Pharmacol Rev       Date:  2013-11-11       Impact factor: 25.468

10.  Correlation between Duffy blood group phenotype and breast cancer incidence.

Authors:  Xiao-Feng Liu; Lian-Fang Li; Zhou-Luo Ou; Rong Shen; Zhi-Min Shao
Journal:  BMC Cancer       Date:  2012-08-28       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.